세계의 약물감시 및 의약품 안전성 소프트웨어 시장 예측(-2030년) : 기능별, 제공 모드별, 최종사용자별, 지역별 분석

According to Stratistics MRC, the Global Pharmacovigilance and Drug Safety Software Market is accounted for $202.6 million in 2023 and is expected to reach $365.8 million by 2030 growing at a CAGR of 8.8% during the forecast period. Pharmacovigilance involves monitoring, assessing, and ensuring the safety of pharmaceutical products post-market approval. Drug Safety Software refers to specialized technology aiding in this process by collecting, managing, and analyzing adverse event data associated with medications. These software solutions streamline reporting, facilitate compliance with regulatory requirements, and enable efficient signal detection, contributing to the continual evaluation and enhancement of drug safety profiles.

According to the National Care Institute 1.7 million new cases of cancer were registered in the U.S. in 2018.

Market Dynamics:

Driver:

Growing complexity of drugs

As drug formulations become more intricate, involving biologics, personalized medicines, and combination therapies, the risk of adverse events intensifies. Advanced pharmacovigilance software plays a pivotal role in managing this complexity by enabling comprehensive monitoring, signal detection, and streamlined adverse event reporting. The software's capacity to handle vast and intricate data sets, coupled with its analytical capabilities, ensures enhanced drug safety surveillance, regulatory compliance, and proactive risk management. Consequently, the growing complexity of drugs propels the demand for sophisticated pharmacovigilance and drug safety software solutions.

Restraint:

High implementation costs

The initial expenses associated with software integration, customization, data migration, and staff training can be substantial. These costs, which include licensing fees and infrastructure investments, can strain budgets, particularly for smaller pharmaceutical companies or healthcare entities with limited resources. Moreover, ongoing maintenance and upgrades further contribute to the total cost of ownership, deterring some organizations from adopting advanced pharmacovigilance software solutions, which further limits the market growth.

Opportunity:

Increasing drug approvals and clinical trials

With an expanding pharmaceutical landscape and a burgeoning number of clinical trials globally, there's a heightened need for robust safety measures and efficient data management. Advanced software solutions offer streamlined adverse event reporting, signal detection, and risk assessment, supporting quicker approvals and ensuring stringent safety compliance. The demand for these software tools is propelled by the industry's focus on accelerating drug development, enhancing patient safety, and complying with evolving regulatory mandates, presenting a ripe opportunity for innovation and adoption within this market.

Threat:

Lack of awareness regarding the benefits of pharmacovigilance software

The lack of awareness regarding the advantages of pharmacovigilance software poses a significant threat to the market. Limited understanding among pharmaceutical companies and healthcare entities about the software's capability to streamline adverse event monitoring, enhance drug safety protocols, and expedite regulatory compliance impedes its adoption. Additionally, insufficient awareness hampers the realization of its potential in reducing risks, improving patient safety and optimizing drug development processes.

COVID-19 Impact:

The COVID-19 pandemic significantly influenced the pharmacovigilance and drug safety software markets. The global urgency for rapid vaccine development and drug approvals prompted heightened regulatory scrutiny and increased pharmacovigilance activities. This surge in demand for robust safety monitoring systems, adverse event tracking, and streamlined reporting mechanisms amplified the adoption of advanced software solutions. Additionally, remote work setups during the pandemic emphasized the need for cloud-based and remote-accessible platforms, accelerating the market's shift towards innovative, scalable, and AI-powered pharmacovigilance software solutions.

The pharmaceuticals & biotechnology companies segment is expected to be the largest during the forecast period

The pharmaceuticals and biotechnology companies segment is anticipated to dominate the pharmacovigilance and drug safety software market due to its substantial investment in research, development, and drug manufacturing. These companies prioritize regulatory compliance and patient safety, necessitating robust pharmacovigilance systems. As the industry faces escalating pressure for enhanced drug safety monitoring and stringent regulatory requirements, these entities increasingly adopt advanced software solutions. These technologies streamline adverse event reporting, signal detection, and risk management, which are crucial in ensuring drug safety, compliance, and efficiency, consequently propelling the pharmaceutical and biotechnology market.

The on-demand/cloud-based (SaaS) segment is expected to have the highest CAGR during the forecast period

The on-demand/cloud-based (SaaS) segment is projected to exhibit the highest CAGR in the pharmacovigilance and drug safety software market. This surge is fueled by the industry's growing preference for flexible, scalable, and cost-effective solutions. Cloud-based platforms offer accessibility, real-time collaboration, and reduced infrastructure costs, aligning well with the evolving needs of pharmaceutical companies. As the demand intensifies for streamlined data management, rapid deployment, and remote accessibility, the SaaS model stands out, driving its remarkable growth.

Region with largest share:

North America is poised to secure the largest market share during the forecast period. This prominence is attributed to the region's robust healthcare infrastructure, substantial investments in technology, and stringent regulatory frameworks mandating stringent drug safety measures. The presence of prominent pharmaceutical companies and a proactive approach toward adopting advanced software solutions further contribute to North America's dominance. With a heightened focus on ensuring patient safety, compliance, and efficient adverse event management, the region emerges as a pivotal hub driving the growth and adoption of pharmacovigilance software solutions.

Region with highest CAGR:

The Asia Pacific region is anticipated to witness the highest growth in the pharmacovigilance and drug safety software market during the forecast period. This upsurge is fueled by the region's expanding pharmaceutical and biotechnology sectors and rapid advancements in healthcare infrastructure. Additionally, increased outsourcing of clinical trials, rising investments in research and development, and a growing focus on healthcare digitization drive the demand for robust pharmacovigilance solutions. With a mounting emphasis on enhancing drug safety, the Asia-Pacific region emerges as a pivotal region for significant market expansion.

Key players in the market:

Some of the key players in Pharmacovigilance And Drug Safety Software Market include Accelovance, ArisGlobal LLC, Cognizant, DXC Technology, Ennov, EXTEDO, FMD K&L Inc., ICON plc, IQVIA, Novartis AG, Oracle Corporation, Parexel International Corporation, Sarjen Systems Pvt. Ltd., SAS Institute Inc., Sparta Systems, Veeva Systems and Wingspan Technology, Inc.

Key Developments:

In October 2023, Ennov is pleased to announce a strategic partnership with ION Pharma. This alliance marks the beginning of a collaborative effort that merges over two decades of expertise in electronic Quality Management Systems (eQMS) with the shared goal of advancing patient outcomes in the Life Sciences sector.

In October 2023, IQVIA, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry announced a strategic collaboration with argenx to advance treatment to patients with rare autoimmune diseases through innovative and integrated technology-enabled pharmacovigilance (PV) safety services and solutions.

In April 2023, Ennov, a leading provider of regulated content and data management software for the Life Sciences industry, is happy to announce that it has acquired UK-based Samarind from its parent company Instem.

Functionalities Covered:

• Adverse Event Reporting Software
• Drug Safety Audits Software
• Fully Integrated Software
• Issue Tracking Software
• Other Functionalities

Mode of Delivery Covered:

• On-Premise
• On-Demand/Cloud-Based (SaaS)

End Users Covered:

• Pharmaceuticals & Biotechnology Companies
• Business Process Outsourcing (BPOs)
• Contract Research Organizations (CROs)
• Research Institutions
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Pharmacovigilance and Drug Safety Software Market, By Functionality

• 5.1 Introduction
• 5.2 Adverse Event Reporting Software
• 5.3 Drug Safety Audits Software
• 5.4 Fully Integrated Software
• 5.5 Issue Tracking Software
• 5.6 Other Functionalities

6 Global Pharmacovigilance and Drug Safety Software Market, By Mode of Delivery

• 6.1 Introduction
• 6.2 On-Premise
• 6.3 On-Demand/Cloud-Based (SaaS)

7 Global Pharmacovigilance and Drug Safety Software Market, By End User

• 7.1 Introduction
• 7.2 Pharmaceuticals & Biotechnology Companies
• 7.3 Business Process Outsourcing (BPOs)
• 7.4 Contract Research Organizations (CROs)
• 7.5 Research Institutions
• 7.6 Other End Users

8 Global Pharmacovigilance and Drug Safety Software Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Accelovance
• 10.2 ArisGlobal LLC
• 10.3 Cognizant
• 10.4 DXC Technology
• 10.5 Ennov
• 10.6 EXTEDO
• 10.7 FMD K&L Inc.
• 10.8 ICON plc
• 10.9 IQVIA
• 10.10 Novartis AG
• 10.11 Oracle Corporation
• 10.12 Parexel International Corporation
• 10.13 Sarjen Systems Pvt. Ltd.
• 10.14 SAS Institute Inc.
• 10.15 Sparta Systems
• 10.16 Veeva Systems
• 10.17 Wingspan Technology, Inc.